Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hypomethylating Agents”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Not applicableStudy completedNCT05456048
What this trial is testing

Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

Who this might be right for
Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaGene Abnormality+1 more
Nanfang Hospital, Southern Medical University 231
Not applicableStudy completedNCT04589728
What this trial is testing

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Who this might be right for
Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 202
Early research (Phase 1)UnknownNCT04999943
What this trial is testing

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesDendritic CellHypomethylating Agents+1 more
Affiliated Hospital to Academy of Military Medical Sciences 40
Post-approval studies (Phase 4)Study completedNCT07773909
What this trial is testing

Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy

Who this might be right for
Acute Myeloid Leukemia
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 24
Testing effectiveness (Phase 2)Looking for participantsNCT03999723
What this trial is testing

Combining Active and Passive DNA Hypomethylation

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia
Kirsten Grønbæk 196
Testing effectiveness (Phase 2)Ended earlyNCT04878432
What this trial is testing

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 39
Early research (Phase 1)Study completedNCT02936752
What this trial is testing

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

Who this might be right for
Myelodysplastic Syndrome
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Ended earlyNCT03151304
What this trial is testing

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Helsinn Healthcare SA 64
Testing effectiveness (Phase 2)Study completedNCT02281084
What this trial is testing

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Celgene 65
Testing effectiveness (Phase 2)Looking for participantsNCT07451912
What this trial is testing

Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML

Who this might be right for
Acute Myeloid Leukemia (AML)CEBPA MutationUnfit, New-diagnosis AML
The First Affiliated Hospital of Soochow University 29
Early research (Phase 1)Study completedNCT02117219
What this trial is testing

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
MedImmune LLC 67
Early research (Phase 1)Study completedNCT05030675
What this trial is testing

Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

Who this might be right for
Refractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center 11
Large-scale testing (Phase 3)UnknownNCT03662087
What this trial is testing

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Who this might be right for
Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation
Nanfang Hospital, Southern Medical University 100
Testing effectiveness (Phase 2)Ended earlyNCT03233724
What this trial is testing

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-Small Cell Lung Cancer+2 more
National Cancer Institute (NCI) 9
Early research (Phase 1)Ended earlyNCT01286038
What this trial is testing

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

Who this might be right for
Myelodysplastic Syndrome (MDS)Thrombocytopenia
H. Lee Moffitt Cancer Center and Research Institute 37
Testing effectiveness (Phase 2)Study completedNCT01246076
What this trial is testing

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Who this might be right for
Myelodysplastic Syndromes
Washington University School of Medicine 24
Testing effectiveness (Phase 2)Ended earlyNCT05918055
What this trial is testing

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
National Cancer Institute (NCI) 3
Testing effectiveness (Phase 2)WithdrawnNCT05766514
What this trial is testing

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
University of Florida
Not applicableActive Not RecruitingNCT07318662
What this trial is testing

Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML

Who this might be right for
MDSCMML
Guangdong Provincial People's Hospital 224
Early research (Phase 1)Study completedNCT02732184
What this trial is testing

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Immedica Pharma AB 21
Next Page